Brigimadlin
- Generic Name
- Brigimadlin
- Drug Type
- Small Molecule
- Chemical Formula
- C31H25Cl2FN4O3
- CAS Number
- 2095116-40-6
- Unique Ingredient Identifier
- 9A934ZAN94
Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development
• Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.
• FDA grants Orphan Drug Designation to Actuate Therapeutics' elraglusib for soft tissue sarcoma treatment, highlighting its potential to address unmet needs in this rare cancer.
• Novel approaches include tumor-targeting antibody-cytokine fusion proteins, intratumoral administration techniques, and GSK-3β inhibition, offering hope for improved outcomes in this challenging disease.
Brigimadlin Shows Promise in Treating Dedifferentiated Liposarcoma
• Brigimadlin (BI 907828) is an oral MDM2-p53 antagonist showing potential in treating dedifferentiated liposarcoma (DDLPS) by restoring normal p53 activity.
• A Phase 1a/1b study indicated brigimadlin has a manageable safety profile, with nausea being the most common adverse effect, and demonstrated stable disease in 75% of liposarcoma patients.
• The ongoing Brightline-1 Phase 2/3 trial is evaluating brigimadlin against doxorubicin as a first-line treatment for advanced or metastatic DDLPS with MDM2 amplification.
• Pharmacists play a crucial role in managing DDLPS patients by providing education, managing toxicity, and assisting with treatment choices based on tumor mutation status.
Boehringer Ingelheim Achieves Significant Pipeline Progress in First Half of 2024
Boehringer Ingelheim has reported significant progress in its pharmaceutical pipeline during the first half of 2024, with notable advancements in cardiovascular, renal, metabolic health, and oncology. The company also experienced a 7.4% year-on-year growth in net sales, driven by high demand for its medications. Key developments include positive Phase II data for survodutide in treating metabolic dysfunction-associated steatohepatitis (MASH) and the initiation of a Phase III trial for a novel selective aldosterone synthase inhibitor in chronic heart failure.
Boehringer Ingelheim Plans 25 New Treatments by 2030, Bolstered by Oncology and Metabolic Disease Programs
• Boehringer Ingelheim aims to launch 25 new treatments by 2030, focusing on oncology, mental health, cardiovascular, renal, and metabolic diseases.
• Key candidates include Brigimadlin, an MDM2-p53 agonist for dedifferentiated liposarcoma, and zongertinib, a HER2 tyrosine kinase inhibitor, showing promising early data.
• Survodutide, a glucagon/GLP-1 candidate, demonstrated significant improvement in liver disease due to metabolic dysfunction-associated steatohepatitis in Phase II trials.
• Despite slow sales of its Humira biosimilar, Cyltezo, Boehringer reported a 9.7% net sales increase in 2023, driven by Jardiance and Ofev.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath